收藏切换
Brief introduction to priority medicines scheme in European Union and its inspiration for China
收藏切换
PDF
Tian-zhu ZENG, Jian-zhou YAN, Rong SHAO
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(9) : 665 - 670
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(9): 665-670
Policy and Management
Brief introduction to priority medicines scheme in European Union and its inspiration for China
Full
Tian-zhu ZENG, Jian-zhou YAN, Rong SHAO
Affiliations
  • The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing JIANGSU 211198, China
Published: 2024-09-25 doi: 10.14109/j.cnki.xyylc.2024.09.06
Outline
收藏切换

To accelerate the development and market launch of new drugs that address unmet clinical needs, the European Medicines Agency (EMA) launched the “priority medicines (PRIME)” scheme in 2016. A range of supportive measures have been provided to drugs granted this qualification at various stages of development, including the appointment of dedicated personnel from EMA to assist applicants, multiple opportunities for applicants to engage in dialogue with regulatory authorities at key developmental stages, assistance in formulating or adjusting drug development plans and regulatory strategies, and facilitating the transition from drug development to market authorization review, thereby expediting the approval process for drug market applications. As of the first half of 2021, EMA had received a total of 384 PRIME qualification applications, of which 95 were approved, covering 19 therapeutic areas including antineoplastic medications, hematological medications, neurological medications, etc. It is suggested that relevant departments in China may draw on the practices of EMA to strengthen the construction in project management, management of communication and exchange meetings, utilization of review resources, and quality management of the review process, in order to improve the system for breakthrough therapeutic drugs in China.

breakthrough therapeutic drug  /  priority medicines scheme  /  European Union  /  drug regulation
Tian-zhu ZENG, Jian-zhou YAN, Rong SHAO. Brief introduction to priority medicines scheme in European Union and its inspiration for China[J]. Chinese Journal of New Drugs and Clinical Remedies, 2024 , 43 (9) : 665 -670 . DOI: 10.14109/j.cnki.xyylc.2024.09.06
Year 2024 volume 43 Issue 9
PDF
116
55
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2024.09.06
  • Receive Date:2023-05-23
  • Online Date:2026-03-18
  • Published:2024-09-25
Article Data
Affiliations
History
  • Received:2023-05-23
  • Accepted:2024-05-14
Funding
Affiliations
    The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing JIANGSU 211198, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.09.06
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT